Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Blood

• Publication date

  2002-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V100.5.1575.H81702001575_1575_1578PMID 12176873
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low-dose daily interleukin-2 immunotherapy: accelerating immune restoration and expanding HIV-specific T-cell immunity without toxicity.

  2001cited by this paper
• Human herpes virus‐8 infection among pregnant women and their children: Results from the sardinia‐IDDM study 2

  2001cited by this paper
• HHV-8 prevalence, immunosuppression and Kaposi's sarcoma in South Italy.

  2001cited by this paper
• Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.

  2001cited by this paper
• Incidence of Kaposi's sarcoma and HHV-8 seroprevalence among homosexual men with known dates of HIV seroconversion

  2000cited by this paper
• Interaction of human immunodeficiency virus type 1 and human herpesvirus type 8 infections on the incidence of Kaposi's sarcoma.

  2000cited by this paper
• Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells.

  2000cited by this paper
• Real-Time Quantitative PCR for Human Herpesvirus 6 DNA

  2000cited by this paper
• Human herpesvirus-8 (HHV-8) gene expression in Kaposi's sarcoma (KS) primary lesions: an in situ hybridization study

  1999cited by this paper
• Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases.

  1999cited by this paper
• Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma.

  1999cited by this paper
• Antibodies against human herpesvirus 8 in black South African patients with cancer.

  1999cited by this paper
• The Enigmas of Kaposi's Sarcoma

  1998cited by this paper
• Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma

  1998cited by this paper
• Human herpesvirus 8 seroprevalence in blood donors and lymphoma patients from different regions of Italy.

  1998cited by this paper
• gamma-Interferon production in peripheral blood mononuclear cells and tumor infiltrating lymphocytes from Kaposi's sarcoma patients: correlation with the presence of human herpesvirus-8 in peripheral blood mononuclear cells and lesional macrophages.

  1998cited by this paper
• Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.

  1998cited by this paper
• gamma-Interferon produced by CD8+ T cells infiltrating Kaposi's sarcoma induces spindle cells with angiogenic phenotype and synergy with human immunodeficiency virus-1 Tat protein: an immune response to human herpesvirus-8 infection?

  1998cited by this paper
• Detection of human herpesvirus 8 DNA in Kaposi's sarcoma lesions and peripheral blood of human immunodeficiency virus-positive patients and correlation with serologic measurements.

  1997cited by this paper
• KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma

  1996cited by this paper
• Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma.

  1996cited by this paper
• The role of cytokines, adhesion molecules, and chemokines in interleukin-2-induced lymphocytic infiltration in C57BL/6 mice.

  1996cited by this paper
• Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity.

  1995cited by this paper
• Interleukin-2 toxicity.

  1991cited by this paper
• Exacerbation of epidemic Kaposi's sarcoma with a combination of interleukin-2 and beta-interferon: results of a phase 2 study.

  1989cited by this paper

• Lymphoma and Epstein−Barr virus DNA in blood during interleukin‐2 therapy in antiretroviral‐naïve HIV‐1‐infected patients: a substudy of the ANRS 119 trial

  2014cites this paper
• Absolute quantification of viral DNA: the quest for perfection.

  2014cites this paper
• Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection

  2013cites this paper
• Molecular study of human herpesvirus 6 and 8 involvement in coronary atherosclerosis and coronary instability

  2012cites this paper
• Interleukine-2 Therapy Does Not Increase the Risk of Hodgkin or Non-Hodgkin Lymphoma in HIV-Infected Patients: Results From FHDH ANRS CO4

  2009cites this paper
• Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy.

  2006cites this paper
• Kaposi's Sarcoma-associated Herpesvirus Activation of Vascular Endothelial Growth Factor Receptor 3 Alters Endothelial Function and Enhances Infection*

  2005cites this paper
• Antitumour effects of antiretroviral therapy

  2004cites this paper
• Epidemiology of HHV-8 infection in HIV-positive patients with and without Kaposi sarcoma: diagnostic relevance of serology and PCR.

  2004cites this paper
• Pathogenesis of Kaposi's sarcoma.

  2003cites this paper
• Calibrated Real-Time PCR Assay for Quantitation of Human Herpesvirus 8 DNA in Biological Fluids

  2002cites this paper